Cargando…

Immunogenicity of a lambda phage-based anti-cancer vaccine targeting HAAH

Detalles Bibliográficos
Autores principales:	Fuller, Steven, Stewart, Solomon, Lebowitz, Michael, Malhotra, Kanam, Semenuk, Mark, Biswas, Biswajit, Ghanbari, Hossein
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3991175/ http://dx.doi.org/10.1186/2051-1426-1-S1-P210

Ejemplares similares

Design, development and production of nano-particle-based anticancer vaccine targeting human aspartyl (asparaginyl) β-hydroxylase (HAAH)
por: Biswas, Biswajit, et al.
Publicado: (2013)

Inhibition of tumor growth in vivo by a nanoparticle-based therapeutic cancer vaccine targeting HAAH
por: Fuller, Steven, et al.
Publicado: (2013)

A nanoparticle therapeutic vaccine targeting HAAH stimulates cellular immunity
por: Lebowitz, Michael, et al.
Publicado: (2015)

A cancer therapeutic nanoparticle vaccine targeting HAAH improves 3-week survival from 12.5% to 100% in a mouse model of metastatic breast cancer
por: Fuller, Steven, et al.
Publicado: (2014)

Enhanced immunogenicity of a nanoparticle therapeutic cancer vaccine targeting HAAH delivered intradermally using 3M's hollow microstructured transdermal system (hMTS)
por: Fuller, Steven, et al.
Publicado: (2015)

Lambda phage-based vaccine induces antitumor immunity in hepatocellular carcinoma
por: Iwagami, Yoshifumi, et al.
Publicado: (2017)

Aspartate β-Hydroxylase (ASPH) Expression in Acute Myeloid Leukemia: A Potential Novel Therapeutic Target
por: Holtzman, Noa G., et al.
Publicado: (2021)

Fusion of CTA and CTB gene to immunogen significantly enhances the immunogenicity of DNA vaccine
por: Ren, X, et al.
Publicado: (2012)

Do circulating HIV vaccine plasmids contribute to immunogenicity in humans?
por: Wahren, B, et al.
Publicado: (2006)

The inhibitory effect of human umbilical cord mesenchymal stem cells expressing anti-HAAH scFv-sTRAIL fusion protein on glioma
por: Xue, Tian, et al.
Publicado: (2022)

Sensitivity of O_R in phage lambda
por: Bakk, A, et al.
Publicado: (2003)

Stable HIV-1 envelope glycoprotein immune complexes as vaccine immunogens
por: van Montfort, Thijs, et al.
Publicado: (2011)

Immunogenic selection of HIV-1 MPER epitopes for improved vaccine design
por: Wieczorek, L, et al.
Publicado: (2012)

Skin tattooing as an effective tool for delivering DNA and protein vaccine immunogens
por: Chiu, Y, et al.
Publicado: (2012)

P05-12. A computationally designed immunogen elicits potent anti-V3 neutralizing antibodies
por: Carrico, CT, et al.
Publicado: (2009)

Engineered gp120 immunogens that elicit VRC01-like antibodies by vaccination
por: Mata-Fink, J, et al.
Publicado: (2012)

P18-13 LB. Immunogenicity of an autologous dendritic cell anti-HIV therapy in HIV-1 infected individuals
por: Yassine Diab, B, et al.
Publicado: (2009)

Sequence and annotation of the Wizard007 mycobacterium phage genome
por: Anyanwu, Ejike, et al.
Publicado: (2010)

Yeast surface display of HIV Env protein variants for the discovery of novel vaccine immunogens
por: Grimm, S, et al.
Publicado: (2012)

P-149: Immunogenicity of SARS-CoV-2 vaccine in patients with multiple myeloma
por: Malard, Florent, et al.
Publicado: (2021)

PReS-FINAL-2032: Changes in immunogenic profile in patients with juvenile idiopathic arthritis exposed to anti tumoral necrosis factor therapy
por: Guillen Astete, CA, et al.
Publicado: (2013)

Discovery and characterization of an immunogenic neoantigen in a patient with metastatic triple negative breast cancer
por: Assadipour, Yasmine, et al.
Publicado: (2015)

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
por: Smith, Andressa A, et al.
Publicado: (2013)

Construction of site selected phage library and characterization of anti-V3 scFvs from Indian clade C HIV-1 infected patient
por: Kumar, R, et al.
Publicado: (2012)

Viral vector delivery of Env trimer immunogens
por: Parks, CL, et al.
Publicado: (2012)

A minimal T-cell immunogen designed to cover HIV-1 specificities associated with control is immunogenic in mice and breaks CTL immunodominance
por: Mothe, B, et al.
Publicado: (2012)

Development of candidate HIV vaccines using VSV vectors to express membrane-anchored MPER immunogen
por: Yuan, M, et al.
Publicado: (2012)

Humoral immunogenicity of ChAd63_MVA ME-TRAP vaccination in African infants and children
por: Bowyer, Georgina, et al.
Publicado: (2014)

Phase I clinical trials of safety and immunogenicity of live cultural influenza vaccine vector-flu
por: Nechaeva, Elena A, et al.
Publicado: (2015)

Liposomal formulation of Gp41 derivate with adjuvant MPLA: vaccine design, immunogenicity in animals and safety in humans
por: Katinger, D, et al.
Publicado: (2012)

P11-18. Immunogenicity of Lactobacillus gasseri-FliC as an oral mucosal vaccine adjuvant for HIV
por: Gunderson, S, et al.
Publicado: (2009)

Immunogenicity of recurrent mutations in MYD88 and EZH2 in non-Hodgkin lymphomas
por: Nielsen, Julie S, et al.
Publicado: (2015)

A171 INTESTINAL INTERFERON-LAMBDA RECEPTOR 1 EXPRESSION AND RESPONSES ARE SIGNIFICANTLY DECREASED IN PEDIATRIC INFLAMMATORY BOWEL DISEASE PATIENTS
por: Ogungbola, O, et al.
Publicado: (2023)

Development of chimeric HIV Env immunogens for mucosal delivery with attenuated canine distemper virus (CDV) vaccine vectors
por: Zhang, X, et al.
Publicado: (2012)

Breadth or conservation score (CS): which is more important for HIV-1 T cell based vaccine immunogen design?
por: Kunwar, P, et al.
Publicado: (2012)

P19-17. Construction of HIV-1 AE subtype gp140 DNA vaccine and immunogenicity evaluation
por: Zhang, C, et al.
Publicado: (2009)

P02-08. Enhancement of HIV-1 DNA vaccine immunogenicity by BCG-PSN, a novel adjuvant
por: Sun, J, et al.
Publicado: (2009)

Murinization of an anti-GITR IgG2c antibody DTA-1 inhibits immunogenicity-mediated anaphylaxis in C57BL/6J mice
por: Alvarez, Hamsell, et al.
Publicado: (2015)

Further confirmation of broadly conserved, highly immunogenic cross-clade HIV CTL epitopes for inclusion in the GAIA HIV vaccine
por: De Groot, AS, et al.
Publicado: (2012)

A dose-escalation clinical trial to evaluate the safety and immunogenicity of a replication-defective HIV-1 vaccine-HIVAX
por: Tung, F, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_3cebfsb0qepln6u87u8ps17f0n